A case of generalized eosinophilic pustular folliculitis: treatment with JAK inhibitor

Abstract

Aim

This case study aims to report the efficacy and safety of a Janus kinase (JAK) inhibitor in the treatment of generalized eosinophilic pustular folliculitis (EPF).

Methods

We present a case of a 16-year-old Chinese patient who had been suffering from EPF for two years and had shown no response to both topical and systemic glucocorticoids. The patient was subsequently treated with oral tofacitinib at a dosage of 5mg daily.

Results

Significant remission of eruption and pruritus was observed in the patient upon treatment with tofacitinib. However, a relapse occurred upon dose reduction. Subsequent switch to the highly selective JAK1 inhibitor upadacitinib resulted in complete recovery, with the patient achieving a symptom-free status after six months.

Conclusions

JAK inhibitors show promise as a potential treatment option for EPF patients who do not respond to traditional therapies.

Keywords:

• Eosinophilic pustular folliculitis
• JAK inhibitor
• eosinophilic pustular folliculitis with follicular mucinosis
• eosinophilic skin diseases

Ethics statement

The patient consent was obtained to publication of the case details in this manuscription.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

All data generated or used during the case appear in the submitted manuscription.

Additional information

Funding

This work was supported by Shandong Provincial Clinical Research Center for Dermatovenerology, the Key Research and Development Program of Shandong Province (2021LCZX07).